Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Towards safer thrombolytic therapy.

Victor J Marder1, Daphne Stewart

  • 1Department of Vascular Medicine, Los Angeles Orthopaedic Hospital, 2400 S Flower Street, Los Angeles, CA 90007, USA.

Seminars in Hematology
|July 19, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

HER2-Low and HER2-Ultralow Metastatic Breast Cancer and Trastuzumab Deruxtecan: Common Clinical Questions and Answers.

Cancers·2025
Same author

ASO Visual Abstract: Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Ovarian Cancer Patients with Peritoneal Metastases-A Multicenter U.S. Phase I Trial.

Annals of surgical oncology·2025
Same author

Safety and Efficacy of Cisplatin and Doxorubicin Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC) in Patients with Ovarian Cancer with Peritoneal Metastases: A Multicenter US Phase I Trial.

Annals of surgical oncology·2025
Same author

MammaTrace - a cell-free DNA methylation plasma only assay for minimal residual disease detection in breast cancer patients.

medRxiv : the preprint server for health sciences·2025
Same author

First-in-human phase I trial of the bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer.

Journal for immunotherapy of cancer·2025
Same author

Impact of Structural Racism and Social Determinants of Health on Disparities in Breast Cancer Mortality.

Cancer research·2024
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Plasminogen activators (PAs) effectively treat clots but carry bleeding risks. Direct plasmin infusion offers a safer, regional thrombolytic alternative, avoiding systemic hemorrhage by localizing clot breakdown.

Area of Science:

  • Cardiovascular Medicine
  • Hematology
  • Pharmacology

Background:

  • Plasminogen activators (PAs) are standard thrombolytic therapies for vascular occlusive diseases.
  • Current PA regimens, including mutant tissue plasminogen activators (tPA), show limited mortality benefits and carry risks of hemorrhagic complications, notably intracranial hemorrhage (ICH).

Purpose of the Study:

  • To explore alternative thrombolytic strategies that mitigate the risk of bleeding associated with conventional PAs.
  • To investigate the potential of direct plasmin infusion for regional thrombolysis.

Main Methods:

  • Review of existing literature on plasminogen activators and thrombolytic therapy.
  • Analysis of the mechanism of action and safety profile of plasmin compared to PAs.
  • Consideration of animal study findings regarding regional plasmin infusion.

Related Experiment Videos

Main Results:

  • Despite advancements, PAs have not surpassed older agents in mortality benefits for acute myocardial infarction.
  • Hemorrhagic complications, particularly ICH, remain a significant concern with PA therapy.
  • Regional plasmin infusion demonstrated efficacy in animal models without systemic bleeding complications due to neutralization by antiplasmin.

Conclusions:

  • A plateau in clinical effectiveness for potent PAs may have been reached, balancing benefit against bleeding risk.
  • Direct regional plasmin infusion presents a promising breakthrough, potentially achieving effective thrombolysis while avoiding systemic hemorrhagic complications.
  • Further research into regional plasmin therapy could lead to safer and more effective treatments for thrombotic events.